Do you want to take the guesswork out of selecting the right patients for the right treatment?
Identify eligible participants for your clinical trial programs in Parkinson’s disease, Alzheimer’s disease, cardiovascular disease and other hereditary diseases. You can do this using a whole exome clinical trial assay. The assay – based on the Helix Laboratory Platform technology and covering 22,000 clinically relevant genes – enables you to select subjects who are most likely to benefit from your new compound.
Together with our partner Helix, we provide flexible global solutions with a centralized (CLIA) testing model for the US and a decentralized (kit-based) model for the EU and other countries.
We provide biopharma companies like yours with a global solution for companion diagnostics (CDx). Our wealth of experience means we can navigate the regulatory path, satisfy regulatory requirements and drive your commercial success.
Call us during our office hours (Monday to Friday): 800-426-8157
For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user operator manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).
This advertisement was sent by QIAGEN. If this email was forwarded to you and you‘d like to receive future communications and advertisements, please sign up here.
